Drug Profile
Research programme: oral insulin - Aphios Corporation
Alternative Names: APH-0907; oral insulin - AphiosLatest Information Update: 25 Nov 2021
Price :
$50
*
At a glance
- Originator Aphios Corporation
- Class Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Pancreatic hormone receptor agonists; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 25 Nov 2021 Preclinical trials in Diabetes mellitus in USA (PO) prior to November 2021 (Aphios Corporation pipeline, November 2021)
- 20 Oct 2014 Research programme: oral insulin - Aphios Corporation is available for licensing as of 20 Oct 2014. http://www.aphios.com/products/therapeutic-product-pipeline/diabetes/aph-0907.html
- 17 Dec 2012 Early research in Diabetes mellitus in USA (PO)